Baguio nurse joins WHO trials for COVID-19 treatment | Inquirer News

Baguio nurse joins WHO trials for COVID-19 treatment

At the height of the lockdown in Baguio City, residents managed To express their gratitude To medical frontliners like the owner of this vehicle along downtown Session Road. VINCENT CABREZA

BAGUIO CITY — The World Health Organization’s “solidarity trials” for a cure to the coronavirus disease (COVID-19) has invited an infected Baguio nurse to participate.

John Delinger Batulan, who works for the Baguio General Hospital and Medical Center, signed up on June 2, the same day a mandatory test confirmed he had contracted the disease, according to the Baguio City public information office on Saturday.

ADVERTISEMENT

The WHO project compares the efficacy of the drug Remdesivir being developed by Gilead Sciences Inc., Lopinavir from the firm Hetero Labs Ltd. and Interferon which is being manufactured by American pharmaceutical company Merck Shark and Dohme.

“I want to be part of the solution to this health problem despite the risks and the challenges. The medicine may not be effective to me but the results will help determine if it can be effective to other patients,” Batulan said in a statement. The nurse is also a cancer survivor.

FEATURED STORIES

Batulan’s brother has also been infected with the disease, based on laboratory results released on June 4.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Health, John Delinger Batulan, Regions, solidarity trials, World Health Organization
For feedback, complaints, or inquiries, contact us.

News that matters



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.